Elisabeth I. Heath, MD, FACP, Karmanos Cancer Institute
Articles by Elisabeth I. Heath, MD, FACP, Karmanos Cancer Institute
IO Therapy in mCRPC and Clinical Pearls
ByAlan H. Bryce, MD,Elisabeth I. Heath, MD, FACP, Karmanos Cancer Institute,Benjamin H. Lowentritt, MD, FACS, Chesapeake Urology,Edwin M. Posadas, MD, FACP, Cedars-Sinai Samuel Oschin Cancer Center,Tian Zhang, MD, MHS, UT Southwestern Medical Center Before sharing clinical pearls for the treatment of prostate cancer, key opinion leaders reflect on the potential use of immune checkpoint inhibitors in mCRPC.
Practical Application of PARP Inhibitors in Metastatic CRPC
ByAlan H. Bryce, MD,Elisabeth I. Heath, MD, FACP, Karmanos Cancer Institute,Benjamin H. Lowentritt, MD, FACS, Chesapeake Urology,Edwin M. Posadas, MD, FACP, Cedars-Sinai Samuel Oschin Cancer Center,Tian Zhang, MD, MHS, UT Southwestern Medical Center Expert panelists consider the real-world application of PARP inhibitor data in patients with metastatic castration-resistant prostate cancer.
Metastatic CRPC: Advent of PARP Inhibitors
ByAlan H. Bryce, MD,Elisabeth I. Heath, MD, FACP, Karmanos Cancer Institute,Benjamin H. Lowentritt, MD, FACS, Chesapeake Urology,Edwin M. Posadas, MD, FACP, Cedars-Sinai Samuel Oschin Cancer Center,Tian Zhang, MD, MHS, UT Southwestern Medical Center Comprehensive insight on the evolving role of PARP inhibitors in metastatic castration-resistant prostate cancer and clinical trials in this setting.
Overview of the Metastatic Castration-Resistant Prostate Cancer Treatment Paradigm
ByAlan H. Bryce, MD,Elisabeth I. Heath, MD, FACP, Karmanos Cancer Institute,Benjamin H. Lowentritt, MD, FACS, Chesapeake Urology,Edwin M. Posadas, MD, FACP, Cedars-Sinai Samuel Oschin Cancer Center,Tian Zhang, MD, MHS, UT Southwestern Medical Center Expert oncologists briefly review the current treatment paradigm of metastatic castration-resistant prostate cancer (mCRPC).
Novel Treatment Modalities in Metastatic Hormone-Sensitive Prostate Cancer
ByAlan H. Bryce, MD,Elisabeth I. Heath, MD, FACP, Karmanos Cancer Institute,Benjamin H. Lowentritt, MD, FACS, Chesapeake Urology,Edwin M. Posadas, MD, FACP, Cedars-Sinai Samuel Oschin Cancer Center,Tian Zhang, MD, MHS, UT Southwestern Medical Center Closing out their segment on metastatic hormone-sensitive prostate cancer, panelists review other treatment modalities being investigated in clinical trials.
Educating Patients on Treatment Options in Metastatic HSPC
ByAlan H. Bryce, MD,Elisabeth I. Heath, MD, FACP, Karmanos Cancer Institute,Benjamin H. Lowentritt, MD, FACS, Chesapeake Urology,Edwin M. Posadas, MD, FACP, Cedars-Sinai Samuel Oschin Cancer Center,Tian Zhang, MD, MHS, UT Southwestern Medical Center Expert insight on methods to educate patients on available treatment options in the setting of metastatic hormone-sensitive prostate cancer.
Metastatic Hormone-Sensitive Prostate Cancer: Data from TITAN and PEACE-1
ByAlan H. Bryce, MD,Elisabeth I. Heath, MD, FACP, Karmanos Cancer Institute,Benjamin H. Lowentritt, MD, FACS, Chesapeake Urology,Edwin M. Posadas, MD, FACP, Cedars-Sinai Samuel Oschin Cancer Center,Tian Zhang, MD, MHS, UT Southwestern Medical Center Key opinion leaders reflect on data from the TITAN and PEACE-1 clinical trials, respectively, in the setting of metastatic hormone-sensitive prostate cancer.
Metastatic Hormone-Sensitive Prostate Cancer: Data From ENZAMET and ARCHES
ByAlan H. Bryce, MD,Elisabeth I. Heath, MD, FACP, Karmanos Cancer Institute,Benjamin H. Lowentritt, MD, FACS, Chesapeake Urology,Edwin M. Posadas, MD, FACP, Cedars-Sinai Samuel Oschin Cancer Center,Tian Zhang, MD, MHS, UT Southwestern Medical Center Shared insight on the ENZAMET and ARCHES clinical trials, which utilized combination enzalutamide strategies in patients with metastatic hormone-sensitive prostate cancer.
Metastatic Hormone-Sensitive Prostate Cancer: Data From ARASENS and ARANOTE
ByAlan H. Bryce, MD,Elisabeth I. Heath, MD, FACP, Karmanos Cancer Institute,Benjamin H. Lowentritt, MD, FACS, Chesapeake Urology,Edwin M. Posadas, MD, FACP, Cedars-Sinai Samuel Oschin Cancer Center,Tian Zhang, MD, MHS, UT Southwestern Medical Center A panel of medical oncologist reflect on clinical data from the ARASENS and ARANOTE trials utilizing combination strategies with darolutamide in mHSPC.
mHSPC: Use of Triplet Therapy
ByAlan H. Bryce, MD,Elisabeth I. Heath, MD, FACP, Karmanos Cancer Institute,Benjamin H. Lowentritt, MD, FACS, Chesapeake Urology,Edwin M. Posadas, MD, FACP, Cedars-Sinai Samuel Oschin Cancer Center,Tian Zhang, MD, MHS, UT Southwestern Medical Center Experts in prostate cancer consider patient suitability for triplet therapy in the setting of metastatic hormone-sensitive disease.
Factors in Selecting Therapy for Patients With Metastatic Hormone-Sensitive Prostate Cancer
ByAlan H. Bryce, MD,Elisabeth I. Heath, MD, FACP, Karmanos Cancer Institute,Benjamin H. Lowentritt, MD, FACS, Chesapeake Urology,Edwin M. Posadas, MD, FACP, Cedars-Sinai Samuel Oschin Cancer Center,Tian Zhang, MD, MHS, UT Southwestern Medical Center A focused review of patient and disease factors that inform selection of therapy for patients with metastatic hormone-sensitive prostate cancer.
Treatment Goals for Patients With Metastatic Hormone-Sensitive Prostate Cancer
ByAlan H. Bryce, MD,Elisabeth I. Heath, MD, FACP, Karmanos Cancer Institute,Benjamin H. Lowentritt, MD, FACS, Chesapeake Urology,Edwin M. Posadas, MD, FACP, Cedars-Sinai Samuel Oschin Cancer Center,Tian Zhang, MD, MHS, UT Southwestern Medical Center Centering discussion on metastatic hormone-sensitive prostate cancer (mHSPC), key opinion leaders identify core goals of treatment.
Optimizing Care for Patients With Non-metastatic CRPC
ByAlan H. Bryce, MD,Elisabeth I. Heath, MD, FACP, Karmanos Cancer Institute,Benjamin H. Lowentritt, MD, FACS, Chesapeake Urology,Edwin M. Posadas, MD, FACP, Cedars-Sinai Samuel Oschin Cancer Center,Tian Zhang, MD, MHS, UT Southwestern Medical Center Before shifting focus away from non-metastatic castration-resistant prostate cancer, medical oncologists reflect on means to optimize care and look to future directions in the field.
Non-metastatic Castration-Resistant Prostate Cancer: Patient Monitoring Strategies
ByAlan H. Bryce, MD,Elisabeth I. Heath, MD, FACP, Karmanos Cancer Institute,Benjamin H. Lowentritt, MD, FACS, Chesapeake Urology,Edwin M. Posadas, MD, FACP, Cedars-Sinai Samuel Oschin Cancer Center,Tian Zhang, MD, MHS, UT Southwestern Medical Center Experts on non-metastatic castration-resistant prostate cancer share insight on patient monitoring strategies to improve outcomes.
Importance of Quality of Life When Choosing Therapy for nmCRPC
ByAlan H. Bryce, MD,Elisabeth I. Heath, MD, FACP, Karmanos Cancer Institute,Benjamin H. Lowentritt, MD, FACS, Chesapeake Urology,Edwin M. Posadas, MD, FACP, Cedars-Sinai Samuel Oschin Cancer Center,Tian Zhang, MD, MHS, UT Southwestern Medical Center A brief discussion on the role of quality of life in selecting best therapy for patients with non-metastatic castration-resistant prostate cancer.
AR Inhibitors in nmCRPC: Real-World Data
ByAlan H. Bryce, MD,Elisabeth I. Heath, MD, FACP, Karmanos Cancer Institute,Benjamin H. Lowentritt, MD, FACS, Chesapeake Urology,Edwin M. Posadas, MD, FACP, Cedars-Sinai Samuel Oschin Cancer Center,Tian Zhang, MD, MHS, UT Southwestern Medical Center Key opinion leaders reflect on the real-world use and data behind AR inhibitors in non-metastatic castration-resistant prostate cancer.
nmCRPC: Clinical Trial Data on AR Inhibitors
ByAlan H. Bryce, MD,Elisabeth I. Heath, MD, FACP, Karmanos Cancer Institute,Benjamin H. Lowentritt, MD, FACS, Chesapeake Urology,Edwin M. Posadas, MD, FACP, Cedars-Sinai Samuel Oschin Cancer Center,Tian Zhang, MD, MHS, UT Southwestern Medical Center Shared insight on the SPARTAN, PROSPER, and ARAMIS studies with androgen receptor (AR) inhibitors in non-metastatic castration-resistant prostate cancer.
Goals of Treatment for Non-metastatic Castration-Resistant Prostate Cancer
ByAlan H. Bryce, MD,Benjamin H. Lowentritt, MD, FACS, Chesapeake Urology,Edwin M. Posadas, MD, FACP, Cedars-Sinai Samuel Oschin Cancer Center,Tian Zhang, MD, MHS, UT Southwestern Medical Center ,Elisabeth I. Heath, MD, FACP, Karmanos Cancer Institute Expert oncologists provide a focused review on goals of therapy for patients with non-metastatic castration-resistant prostate cancer (nmCRPC).
Expert oncologists Tanya Dorff, MD, and Elisabeth Heath, MD, FACP, reflect on the current treatment paradigm for patients with metastatic castration-resistant prostate cancer (mCRPC).
Elisabeth I. Heath, MD, FACP, discusses developments in nonmetastatic castration-resistant prostate cancer (CRPC).
Elisabeth I. Heath, MD, FACP, discusses a remaining challenge in nonmetastatic castration-resistant prostate cancer.
Elisabeth I. Heath, MD, FACP, discusses apalutamide, enzalutamide, and darolutamide, which have all been approved for use in nonmetastatic castration-resistant prostate cancer.
Elisabeth I. Heath, MD, FACP, discusses the safety profiles of apalutamide, enzalutamide, and darolutamide in nonmetastatic castration-resistant prostate cancer.
IO Therapy in mCRPC and Clinical Pearls